A Study Evaluating the Efficacy and Safety of Clascoterone Cream 1% in Skin of Color Patients With Acne

Inclusion Criteria

• •i. Outpatient, male or female subjects of any race (Fitzpatrick skin types IV, V, VI), and at least 12 years of age or older. Female subjects of childbearing potential must have a negative urine pregnancy test result at Baseline (test must have a sensitivity of at least 25mIU/ml for human chorionic gonadotropin) and practice a reliable method of contraception throughout the study:
• •A female is considered of childbearing potential unless she is:
• •postmenopausal for at least 12 months prior to study drug administration;
• •without a uterus and/or both ovaries; or
• •has been surgically sterile for at least 6 months prior to study drug administration.
• •Reliable methods of contraception are:
• •hormonal methods or intrauterine device in use \> 90 days prior to study drug administration;
• •barrier methods plus spermicide in use at least 14 days prior to study drug administration; or
• •vasectomized partner (vasectomy must be performed 3 months prior to first study drug administration or in the alternative a zero sperm count will suffice)
• •\[Exception: Female subjects of childbearing potential who are not sexually active will not be required to practice a reliable method of contraception. These subjects may be enrolled at the Investigator's discretion if they are counseled to remain sexually inactive during the study and understand the possible risks in getting pregnant during the study.\] ii. Facial acne IGA score of 3 or 4. iii. Able to understand the requirements of the study and sign Informed Consent/HIPAA Authorization forms. Subjects under the legal age of consent in the state where the study is conducted must also have the written, informed consent of a parent or legal guardian.